Denosumab-Mobz
Denosumab-Mobz is a monoclonal antibody that belongs to the RANKL inhibitor class of medications, designed to reduce bone resorption and increase bone mass. It is primarily used in patients with osteoporosis, bone loss from certain cancer treatments, or conditions involving excessive bone breakdown. As a pin-variant formulation, this medication may offer specific administration or absorption characteristics compared to standard formulations.
A bone-targeting monoclonal antibody that inhibits bone breakdown to treat osteoporosis and bone-related conditions.
Key facts at a glance
- RxNorm
- 2729308
- Generic
- Denosumab-Mobz
- Class
- pin-variant
- Brands
- Boncresa, Oziltus
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- —
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Treatment of osteoporosis in postmenopausal women and men at high risk for fractures, management of bone loss in patients receiving certain cancer therapies, and reduction of skeletal-related events in patients with bone metastases from solid tumors.
Acts as a monoclonal antibody that binds to RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand), blocking its interaction with RANK receptors on osteoclast precursors. This inhibits the formation, function, and survival of osteoclasts, thereby reducing bone resorption and increasing bone density.
Administered as a subcutaneous injection typically every 6 months for osteoporosis indications. May increase risk of hypocalcemia, particularly in patients with renal impairment. Osteonecrosis of the jaw and atypical femur fractures are rare but serious potential adverse effects. Not recommended during pregnancy. Patients should maintain adequate calcium and vitamin D intake during treatment.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 25, 2026. · Read our editorial policy